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a b s t r a c t
Background and purpose: Accurate delineation of the primary tumour is vital to the success of radiotherapy
and evenmore important for successful boost strategies, aiming for improved local control in oesophageal
cancer patients. Therefore, the aim was to assess delineation variability of the gross tumour volume (GTV)
between CT and combined PET-CT in oesophageal cancer patients in a multi-institutional study.
Materials andmethods: Twenty observers from14 institutes delineated the primary tumour of 6 cases onCT
and PET-CT fusion. The delineated volumes, generalized conformity index (CIgen) and standard deviation
(SD) in position of the most cranial/caudal slice over the observers were evaluated. For the central delin-
eated region, perpendicular distance betweenmedian surface GTV and each individual GTVwas evaluated
as in-slice SD.
Results: After addition of PET, mean GTVs were significantly smaller in 3 cases and larger in 1 case. No dif-
ference in CIgen was observed (average 0.67 on CT, 0.69 on PET-CT). On CT cranial-caudal delineation vari-
ation ranged between 0.2 and 1.5 cm SD versus 0.2 and 1.3 cm SD on PET-CT. After addition of PET, the
cranial and caudal variation was significantly reduced in 1 and 2 cases, respectively. The in-slice SD was
on average 0.16 cm in both phases.
Conclusion: In some cases considerable GTV delineation variability was observed at the cranial-caudal bor-
der. PET significantly influenced the delineated volume in four out of six cases, however its impact on obser-
ver variation was limited.
 2018 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Oesophageal cancer is the eighth most common malignancy in
the world and the incidence is rising [1]. The addition of neoadju-
vant chemoradiation (nCRT) to surgery in the curative treatment of
oesophageal cancer patients has resulted in downstaging, more
radical resections and a survival benefit [2,3]. Definitive chemora-
diation (dCRT) is the treatment of choice for inoperable or irre-
https://doi.org/10.1016/j.ctro.2018.10.003
2405-6308/ 2018 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: GTV, gross tumour volume; CIgen, generalized conformity index; SD, standard deviation; nCR, neoadjuvant chemoradiation; dCRT, definitive
chemoradiation; AJCC, American Joint Committee on Cancer; EGJ, oesophageal-gastric junction; SUV, standardized uptake volume.
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sectable oesophageal cancer patients. Loco-regional recurrences
are still considerable (30–60%) and mainly occur at the site of
the primary tumour [4–9].
However, evidence is rising that a simultaneous-integrated
boost to gross primary disease in locally advanced oesophageal
cancer may improve local control for patients with unresectable
cancer [10]. Therefore, prospective dose-escalation trials are pre-
sently enrolling patients for dose intensification to the primary
tumour aiming for improved local tumour control [11,12]. The
Dutch national trial is randomizing between the standard dose of
50.4 Gy and an experimental dose of 61.6 Gy in 28 fractions to
the primary tumour [11].
Accurate delineation of the primary tumour is vital to the suc-
cess of radiotherapy and even more important for successful boost
strategies. Moreover, when the results of dose-escalation studies
are interpreted, it is essential to be aware of the interobserver vari-
ation of the GTV delineation of the primary tumour.
Furthermore, for patients with a pathologic complete response
after nCRT, there is on-going debate if those patients can be treated
with organ sparing strategies [13]. Improving GTV definition and
thus increasing the chance of a complete response is essential for
the success of organ sparing strategies. Therefore, for both dCRT
and for nCRT patients, accurate delineation of the gross macro-
scopic tumour is essential.
For years, computed tomography (CT) has been used for delin-
eation of oesophageal target volumes during radiotherapy treat-
ment planning. However, determination of the proximal and
distal extension of the primary tumour is often difficult on CT
due to poor soft tissue contrast. Assessment of oesophageal tumour
length by CT might overestimate the extension compared to
histopathology [14]. Endoscopic Ultrasound (EUS) seems more
accurate in assessing the longitudinal oesophageal tumour exten-
sion [15]. However, translation of EUS findings into the RT plan-
ning process is difficult.
Endoscopy-guided clipping or fiducial insertion at the tumour
borders might serve as a valid option for GTV definition, although
this adds an additional invasive procedure [16].
Fluorodeoxyglucose (FDG) uptake is seen in 68–100% of oeso-
phageal tumours [17]. FDG-PET is superior to CT in detecting nodal
and distant metastases [18], therefore adding value to the (re-)
staging of oesophageal tumours [19].
In clinical practice, fused PET-CT images are often used for oeso-
phageal tumour delineation and this seems to improve accuracy in
target contouring. However, previous studies are mostly single-
center studies or assessed a limited number of observers [20–27].
The aims of this study were to evaluate the interobserver delin-
eation variation of the primary oesophageal tumour in daily clini-
cal practice in The Netherlands, and to study the effects of the
addition of FDG-PET to CT images on interobserver variability in
a nationwide multi-institutional setting.
2. Materials and methods
2.1. Patients and observers
All 21 radiotherapy institutes in the Netherlands were
approached to participate. Imaging of six locally advanced oeso-
phageal cancer patients was selected from a previous study, in
which the response of oesophageal tumours to nCRT was evaluated
with different imaging modalities. This study was approved by the
local medical ethics committee and written informed consent was
obtained from all patients (NCT 02125448). Cases were selected
based on availability of a planning PET-CT in radiotherapy position,
tumour location according to the American Joint Committee on
Cancer (AJCC) classification [28], and histology. To represent daily
clinical practice, we included cases equally spread along the
oesophagus, and both squamous cell and adenocarcinoma cases
(Table 1).
2.2. FDG-PET/CT scans
All patients underwent a planning 18F-FDG-PET/CT scan in
radiotherapy treatment position between December 2013 and
December 2014. Patients had to stay sober for at least six hours
before injection of 18F-FDG, and blood glucose levels were mea-
sured for potential hyperglycemia. The administered activity of
intravenously administered 18F-FDG was 2.0 MBq/kg. Approxi-
mately 60 min after administration of 18F-FDG, PET and CT imag-
ing were performed from neck to abdomen using a 18F-FDG PET/
CT system (Siemens, Erlangen, Germany). Before PET acquisition
a diagnostic quality Iodine contrast-enhanced CT was performed
with the following settings: 120 kV, 20 mA, 0.5 s tube rotation
time, pitch of 1.0, and 3.0 mm slice width. PET was performed
using 3-dimensional acquisition, an axial field of view of
216 mm, and a scanning time of 3 min/bed position. 18F-FDG
PET/CT data were reconstructed using iterative ordered-subsets
expectation maximization for 21 subsets and 4 iterations (Gaus-
sian filter). CT images were reconstructed with slice thickness of
3 mm. Administration of oral and intravenous contrast agents
was performed in all cases.
2.3. Delineation software and study outline
DICOM files with the co-registered CT and PET data and a digital
manual were sent to all observers. Basic clinical information (age,
gender, histology and endoscopy-EUS report) and imaging infor-
mation (CT and PET report) were provided. All observers delineated
the gross tumour volumes according to institutional guidelines and
used their own delineation software, preventing observer variation
by facing new delineation software. GTV definition was not stan-
dardized since the aim of this study was to reveal interobserver
variability in a multi-institutional setting in current clinical prac-
tice. The digital manual stated to delineate all macroscopic primary
tumour, except pathological lymph nodes, conform institutional
guidelines. To standardize the window-level of FDG-PET scans for
tumour delineation, the mean activity in the liver was used as ref-
erence value for physiological soft tissue uptake of FDG under fast-
ing conditions [29]. A nuclear medicine physician standardized this
pre-set for all cases. In the first phase, observers delineated the
GTV of the primary tumour on CT (GTV_CT), based on all available
clinical and diagnostic information. Observers were provided with
the FDG-PET/CT report, however were not allowed to review the
non-co-registered PET/CT on a second screen. In the second phase,
this delineation on CT was adjusted after co-registration and visual
interpretation of the FDG-PET scan, creating a second GTV
(GTV_PET).
2.4. Contour analysis
The mean and standard deviation of the delineated target vol-
umes was calculated per patient and compared subsequently
between the first phase and the second phase. To quantify the
overlap between CT and FDG-PET/CT based target volumes for each
patient, the generalized conformity index (CIgen) was calculated
[30]. The CIgen is the sum of the common volumes between obser-
ver pairs divided by the sum of the encompassing volumes
between each pair of observers. A CIgen of 1 represents perfectly
overlapping structures with identical volume, location and shape.
A CIgen of 0 means there is no overlap. The cranial and caudal
delineation variation was calculated as the standard deviation in
the position of the most proximal and distal delineated slice over
34 M.E. Nowee et al. / Clinical and Translational Radiation Oncology 14 (2019) 33–39
the observers [31]. For the central delineated region, designated as
the GTV by all observers, a surface distance variation was calcu-
lated. The interobserver delineation variation was assessed relative
to a reference contour for each patient, the median surface GTV,
which was computed in three dimensions [32]. The median sur-
face, encompassing 50% coverage of the GTVs of all observers,
was subsequently sampled using 8000 equally distributed points.
For each point the perpendicular distance to each delineated GTV
surface was calculated. The variation of the different observers
for each point on the median surface was expressed in a local
observer variation (local SD). For the central delineated region,
the overall observer variation was calculated for each patient as
the quadratic mean of the local SD, representing in-slice SD. Anal-
yses were performed with in-house developed software [31].
2.5. Statistical methods
Mean volumes and generalized conformity indices were com-
pared using a pairwise t-test (paired 2-sided Student’s t-test). To
compare standard deviations a 2-sided F-test was used (Microsoft
Excel). P-values lower than 0.05 were considered to be statistically
significant.
3. Results
A total of 20 upper gastro-intestinal dedicated radiation oncol-
ogists from 14 different radiotherapy institutes participated in this
study. The baseline characteristics of the six patients used for
delineation are shown in Table 1. For case no. 6 the GTV_PET target
volume was missing from 1 observer, therefore 19 observers were
included in the analysis of this case.
3.1. Phase 1 – delineation on CT
Interobserver delineation variation on CT was in some cases
substantial, as shown in Fig. 1A. Mean delineated volumes of the
6 individual cases ranged from 13.3 cm3 to 65.8 cm3 (Table 2).
The CIgen on CT ranged from 0.58 to 0.76 and was on average
0.67 (Table 2).
The local surface distance variation (1SD) of the 20 observers
projected on the median surface of each of the 6 cases is shown
in Fig. 2. The main variation between observers on CT was found
in the definition of the cranial and caudal border of the GTV. In
patient 1, for example, cranial border differences up to 3.6 cm were
seen between observers, resulting in a cranial delineation variation
of 1.5 cm (1SD) (Table 2). Cranial delineation variation ranged
between 0.3 and 1.5 cm SD with an average of 0.99 cm SD, while
caudal variation ranged from 0.2 to 1.0 cm SD, with an average of
0.75 cm SD. The in-slice variation on CT in the central region, des-
ignated as the GTV by all observers, was small. The central overall
SD ranged between 0.10 and 0.25 cm with an average of 0.16 cm
SD (Table 2).
3.2. Phase 2-delineation on PET-CT
Large differences in observer delineations were also present in
phase 2, as shown in Fig. 1B. Mean delineated volumes of the 6
individual cases ranged from 12.4 cm3 to 76.7 cm3 (Table 2).
CIgen’s of the 6 cases ranged from 0.56 to 0.77 with an average
of 0.69 for FDG-PET/CT based delineations.
The local surface distance variation (1SD) of the 20 observers
projected on the median surface of each of the 6 cases after addi-
Table 1
Baseline characteristics of the six oesophageal cancer cases.
Case no. cTNMy AJCC location* Histology Male/Female Age (yr)
1 T3N2M0 Upper thoracic SCC M 67
2 T3N1-2M0 Middle thoracic SCC M 54
3 T2N2M0 Lower thoracic, EGJ1 AC M 71
4 T3N2-3M0 Lower thoracic, EGJ AC F 70
5 T2N0-1M0 Lower thoracic AC M 64
6 T3N1M0 Upper thoracic SCC F 74
Abbreviations: no. = number; yr = years; M = Male; F = Female; SCC = squamous cell carcinoma; AC = adenocarcinoma.
y Clinical tumour-node-metastasis (cTNM) stage according to 7th edition TNM classification.
* American Joint Committee on Cancer (AJCC) classification 2012.
1 Lower thoracic tumour including the oesophageal-gastric junction (EGJ).
Fig. 1. Delineation variation in case 1 for 20 observers. 1A (phase 1). The GTV of the
primary tumour was delineated by 20 observers on CT, with available clinical and
diagnostic information. 1B (phase 2). After fusion of the FDG-PET scan, the GTV was
adjusted based on the visual interpretation of the FDG-PET scan. The colour wash
image indicates the intensity of the SUV signal. This case contained satellite lesions
proximal of the tumour. Although the presence of satellite lesions was included in
the clinical information, these were included in the GTV by only 9 and 11 of the 20
observers in phase 1 and 2 respectively.
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tion of PET data to the CT data is shown in Fig. 2. Similar to phase 1,
delineation differences between observers on CT + PET were
mainly located at the cranial and caudal border. In patient 1, cra-
nial border differences of up to 4.8 cm were observed between
observers, resulting in a cranial delineation variation of 1.3 cm
(1SD) (Table 2). In phase 2, cranial and caudal delineation variation
ranged between 0.3–1.3 cm SD and 0.2–0.8 cm SD, with an average
of 0.81 cm SD and 0.61 cm SD, respectively (Table 2). The in-slice
Table 2
Volumetric analysis and interobserver variation in CT and FDG-PET/CT based GTV delineations of six oesophageal cancer patients for 20 observers.







Central overall SD (RMS, cm)
CT FDG-PET/CT p* CT FDG-PET/CT CT FDG-PET/CT p** CT FDG-PET/CT p** CT FDG-PET/CT
1 51.0 53.1 0.362 0.67 0.69 1.5 1.3 0.597 0.9 0.4 0.002 0.17 0.17
2 54.2 49.2 0.001 0.76 0.77 0.3 0.4 0.295 1.0 0.5 0.005 0.17 0.15
3 65.8 76.7 0.002 0.66 0.69 1.1 0.4 <0.001 0.7 0.8 0.526 0.12 0.13
4 52.0 45.0 0.005 0.62 0.65 1.0 0.9 0.594 0.8 0.7 0.671 0.25 0.25
5 28.3 26.8 0.402 0.58 0.56 1.1 1.0 0.792 0.6 0.8 0.165 0.10 0.09
6 13.3 12.4 0.020 0.75 0.76 0.3 0.3 0.556 0.2 0.2 0.978 0.11 0.10
Abbreviations: CT = computed tomography; FDG-PET = fluorodeoxyglucose-positron emission tomography; SD = standard deviation; CIgen = generalized conformity index
(sum of the common divided by the sum of the encompassing volumes between each pair of observers). Cranial/caudal delineation variation = SD in the position of the most
cranial/caudal delineated slice over the observers. Central overall SD = quadratic mean of the local SD weighted for surface (RMS = Root Mean Square) of the central part of the
median surface where 100% of the observers agreed to delineate.
* p < 0.05 considered statistically significant, one-sample T-test (2-tailed).
** p < 0.05 considered statistically significant, 2-sided F-test.
Fig. 2. Local surface distance variation (1SD) over the 20 observers projected on the median surface of the 6 patients. AP = anterior-posterior view; PA = posterior-anterior
view.
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SD (central overall SD) was small and ranged between 0.09 and
0.25 cm SD with an average of 0.16 cm SD (Table 2).
3.3. Comparison of phase 1 and 2: delineation on CT versus on PET-CT
After addition of FDG-PET to CT, the mean GTV significantly
changed in 4 out of 6 cases (Table 2). In 3 cases the GTV was
reduced after addition of PET, whereas in the other case a volume
increase was observed. CIgen’s of the 6 cases were comparable
between phase 1 and 2, as shown in Table 2 (p = 0.14).
The addition of FDG-PET reduced the cranial delineation varia-
tion significantly in one case from 1.1 to 0.4 cm SD (case no. 3;
p < 0.001). In two cases the caudal delineation variation was signif-
icantly reduced with CT + PET from 0.9 to 0.4 cm SD and from 1.0
to 0.5 cm SD, respectively (case no. 1, p = 0.002 and case no. 2,
p = 0.005; Table 2). Even after addition of FDG-PET cranial or caudal
delineation variation remained more than 0.6 cm SD in 4 out of 6
cases, including all lower thoracic/oesophageal-gastric junction
tumours (case 3, 4, 5).
For the central region, FDG-PET had no added value in-slice and
the overall variation was on average 0.16 cm SD for phase 1 and
phase 2 (Table 2).
4. Discussion
In this nationwide study, we demonstrated that delineation
variation of the primary tumour GTV can be considerable both
on CT and on PET-CT fusion, and is mainly located at the cranial
and caudal border. Although the addition of FDG-PET to CT signif-
icantly impacted the delineated volume in two-third of the cases,
PET did not translate into reduced observer variation at the cra-
nial/caudal border in 50% of the cases.
Combined PET-CT imaging is often used for oesophageal
tumour delineation. Previous studies showed that PET-CT imaging
might impact the GTV delineations in up to 84% of patients [22,24–
27]. Comparably, we found a significant change of the mean vol-
ume in 4/6 of cases, meaning that the addition of PET drives clini-
cians to alter their delineations substantially. In studies with
surgical pathology confirmation, metabolic tumour length on
PET-CT of surgically treated oesophageal carcinoma patients corre-
lated well with histopathology [33–35], while oesophageal tumour
length assessed using CT did not reflect pathological tumour length
[14,15,36]. Observers have a tendency to overestimate tumour
length on CT with marked inter- and intra-observer variability. In
the largest study with 56 cases tumour lengths on CT were in
68% longer compared to pathology, with a mean difference of
1.67 cm [14]. In our study, surgical pathology conformation was
not possible due to the small number of patients and the use of
neoadjuvant chemoradiation, but mean volume on CT was signifi-
cantly reduced by addition of PET in 3 cases and increased in 1
case, suggesting a similar effect.
Interobserver variability can be used as a surrogate to test the
complementary value of PET to CT-delineation, assuming lower
interobserver variability represents more accurate delineation.
Data are scarce and conflicting. Vesprini et al. found improvement
in delineation variability with the addition of PET imaging infor-
mation. The SD for both GTV length and volume was taken as inter-
observer variability [20]. Scheurs et al. found no significant effect
on interobserver variability by the addition of PET, computing an
interobserver concordance index (dividing the volume intersec-
tions of one observer pair by the volume unions of that observer
pair) [21]. In our study the conformity index of the 6 cases was
comparable between phase 1 and 2. However, we found that the
addition of PET reduced the cranial/caudal delineation variation
in 3 out of 6 cases.
Remarkably, in some cases still large observer variation was
present after PET-CT fusion. Cranial delineation variation was most
pronounced in case 1, a patient in which gastroscopy showed satel-
lite lesions proximal of the tumour. Although the presence of satel-
lite lesions was included in the clinical information, these were
included in the GTV by only 9 and 11 of the 20 observers in phase
1 and 2 respectively.
Instructions for delineation in this study were to delineate GTV
volumes according to institutional guidelines. The aim was to clar-
ify the amount of variation in current clinical practice. Most guide-
lines recommend to contour the entire circumference when
contouring the GTV [37], however, individual interpretation of
those guidelines might vary as shown in case 1. With regard to
boost targets in dose escalation studies, GTV definition should be
evident for valuable interpretation of results. Clear GTV definition
may have a big effect on target volume delineation.
The two cases including the oesophageal-gastric junction (EGJ;
case 3 and 4), showed substantial observer variation at the caudal
border even after the addition of PET, showing lack of consensus
when delineating the ingrowth of the cardia. However, PET did
show an impact on the delineated volume in both cases.
A possible explanation for these large variations could be a dif-
ference when interpreting clinical and diagnostic information for
delineation and also institutional differences in target definition.
Agreement on the GTV definition and international GTV guidelines
are warranted to overcome these large variations. With better
agreement by delineation guidelines and by training of radiation-
oncologists, variations in target volume dimensions could further
be reduced [38].
Furthermore, we expected that PET would facilitate demarcat-
ing the caudal border of lower thoracic and EGJ tumours, where
visualization on CT is poor [39]. PET might help to determine the
distal borders, unfortunately gastritis can also cause FDG uptake.
In our study, the caudal variation was not significantly reduced
after PET addition in lower thoracic and EGJ tumours. Endoscopy-
guided clipping or fiducial insertion at the distal tumour border
might overcome this difficulty [16].
Additionally, co-registering PET-CT images for oesophageal tar-
get volume definition has some limitations. Firstly, not all oesopha-
geal carcinomas are FDG avid [17]. Secondly, FDG-PET images do
not provide accurate information on the external and internal con-
tour of the tumour because of the limited spatial resolution [40].
Thirdly, target volume extension can depend on the threshold cho-
sen and enlarged or decreased depending on the windowing. And
finally, PET image acquisition covers all phases of the respiratory
cycle and thus oesophageal tumour motion blurs the tumour bor-
ders [41]. Literature on 4 Dimensional (4D) CT shows main primary
tumour motion for distal tumours in cranial-caudal direction [42]
and the effects of tumour motion will especially play a role in
PET visualization of lower tumours [43]. The use of 4D CT and 4D
PET-CT might be worthwhile exploring in future research.
Because of these limitations it has been suggested that
increased uptake should be used only for tumour localization and
not to define precise boundaries. Threshold based delineation
might overcome these shortcomings in the future. Different
threshold methods have been evaluated, e.g. an isocontour of the
standardized uptake volume (SUV) of 2.5, a predefined percentage
of the maximum SUV, or a gradient based method [44], although
no consensus seems to emerge [45,46].
Moreover, magnetic resonance imaging (MRI) provides better
soft tissue contrast and diffusion-weighted MRI has the advantage
of additional functional information. For many tumour sites MRI
has additional value for delineation and the role of MRI for oeso-
phageal GTV delineation might be worthwhile exploring [47].
To our knowledge, this is the first multi-institutional, nation-
wide delineation study for oesophageal cancer patients to date rep-
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resenting observer variation of the primary tumour GTV in daily
clinical practice.
Solutions to reduce delineation variation might have great
impact on daily clinical practice. We warrant international consen-
sus guidelines for delineation of the primary tumour GTV and
research to define the distal tumour extent more clearly is encour-
aged especially for lower thoracic/EGJ tumours.
5. Conclusion
Inter-observer variability in primary tumour delineation was in
some cases substantial and mainly located at the cranial and cau-
dal border. Fusion of CT with PET influenced the delineated volume
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